Therapeutics

Q3 2026 delivered advances in some closely watched pipeline products.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

Women are more often affected than men, and the disease manifests differently between the sexes.

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

Darovasertib–crizotinib extends PFS and drives 37% responses in HLA-A*02:01-negative metastatic uveal melanoma, paving path to approval.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

China clears first mite-targeting drop for Demodex blepharitis, bringing XDEMVY-style relief and new options beyond lid scrubs and tea tree oil.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

University of Utah data show US ophthalmic drug and eye drop shortages last longer and occur more often, affecting local and systemic medications equally.

PULSAR post-hoc finds aflibercept 8 mg matches 2 mg for PCV, offering 12–16-week dosing and reduced injection burden.

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

FDA clears DifGen’s generic fluorometholone 0.1% eye drop suspension, expanding lower-cost options for anterior eye inflammation and steroid care.

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

Lab tests show red‑light myopia devices exceed ANSI safety limits in seconds, fueling urgent calls for independent validation before kids use them.

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

Strategies for treatment intervals, drug selection, and patient expectations.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.